Access
This article is part of Nature's premium content.
Published online 23 September 2008 | 455, 437 (2008) | doi:10.1038/455437a
News
Monoclonal antibodies come of age
Biotechs look to 'passive immunity' therapies.
A fast way of isolating antibodies from people has been used to create a library of the immune proteins produced by someone inoculated with a nicotine-acting vaccine. Roger Beerli and his team at Cytos Biotechnology in Schlieren, Switzerland, used lymphocytes from an individual who was enrolled in a clinical trial of the smoking-cessation vaccine, and with their technique rapidly identified nicotine-specific antibodies1.
To read this story in full you will need to login or make a payment (see right).
Comments
Reader comments are usually moderated after posting. If you find something offensive or inappropriate, you can speed this process by clicking 'Report this comment' (or, if that doesn't work for you, email webadmin@nature.com). For more controversial topics, we reserve the right to moderate before comments are published.
There are currently no comments.
